Stockscreener 앱 받기
183.46
0.69%
-1.28
시간 외 거래:
185.69
2.23
+1.22%
Astrazeneca Plc 주식(AZN)의 최신 뉴스
Strong Results and Improved Guidance Lifted AstraZeneca PLC (AZN) - Yahoo Finance
AstraZeneca stock drops 2.88% as shares remain below recent trading averages - Traders Union
ASTRAZENECA : Bernstein reaffirms its Buy rating - marketscreener.com
Is AstraZeneca PLC (AZN) A Good Stock To Buy Now? - Yahoo Finance
AstraZeneca invests £300 million in UK drug development sites - marketscreener.com
FTSE 100 Today Focus on BP plc (LSE:BP), Shell plc (LSE:SHEL) and AstraZeneca plc (LSE:AZN) - Kalkine Media
Astrazeneca Plc $AZN Shares Sold by D.A. Davidson & CO. - MarketBeat
MSN Money - MSN
Fidelity Sustainable International Equity Fund's AstraZeneca PLC(LSE:AZN) Holding History - GuruFocus
UK's FTSE 100 slips as losses in energy stocks and AstraZeneca weigh - marketscreener.com
UK's FTSE 100 Closes Lower; NatWest, AstraZeneca Shares Down - marketscreener.com
AstraZeneca updates voting rights and admits new shares to London Stock Exchange - Investing.com
Employee share plans add 14,807 AstraZeneca (AZN) shares to LSE - Stock Titan
FDA advisory committee does not support AstraZeneca’s camizestrant for breast cancer - Investing.com
AstraZeneca (AZN) Stock Drops as Breast Cancer Drug Fails to Win Over FDA Advisors - CoinCentral
FDA advisory panel recommends AstraZeneca’s Truqap for PTEN-deficient prostate cancer - Investing.com Nigeria
FDA panel opposes benefit-risk profile of AstraZeneca (AZN) camizestrant combo - Stock Titan
FDA panel supports AstraZeneca (NYSE: AZN) Truqap combo for PTEN-deficient prostate cancer - Stock Titan
FTSE 100 drops in thin trading as NatWest, AstraZeneca weigh - Moneycontrol.com
AstraZeneca wins FDA AdCom backing for Truqap (AZN:NYSE) - Seeking Alpha
AstraZeneca Prostate Drug Wins FDA Panel Backing As Breast Cancer Candidate Falters - Benzinga
State Street International Developed Equity Index Portfolio's AstraZeneca PLC(LSE:AZN) Holding History - GuruFocus
AstraZeneca (NYSE: AZN) Posts Revenue Above $15bn in Q1 - Value The Markets
AstraZeneca Faces Setback as Drug Review Stirs Market Focus - Kalkine Media
AstraZeneca shares drop after US regulators vote against breast cancer drug - marketscreener.com
Why is AstraZeneca stock down today? - Traders Union
AstraZeneca falls as FDA advisers reject breast cancer drug use - Proactive financial news
AstraZeneca Shares Weaken After FDA Panel Rejects Camizestrant - Yahoo Finance UK
AstraZeneca PLC expected to post earnings of $2.58 a shareEarnings Preview - TradingView
AstraZeneca's Breast-Cancer Candidate Drug Loses FDA Panel Vote -- Update - marketscreener.com
AstraZeneca slips after FDA panel rejects breast cancer drug camizestrant By Investing.com - Investing.com Nigeria
AstraZeneca shares drop after US regulatory panel votes against breast cancer drug - Reuters
AstraZeneca shares dip after US regulatory panel rejects breast cancer drug - marketscreener.com
AZN Forecast, Price Target & Analyst Ratings | ASTRAZENECA PLC-SPONS ADR (NYSE:AZN) - ChartMill
Sit ESG Growth Fund's AstraZeneca PLC(AZN) Holding History - GuruFocus
US FDA Committee Votes Against Combination Formulation Featuring AstraZeneca's Camizestrant - marketscreener.com
AstraZeneca's Truqap Recommended by US FDA's Oncologic Drugs Committee - marketscreener.com
AstraZeneca : Truqap recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer - marketscreener.com
Alger Growth & Income Portfolio's AstraZeneca PLC(AZN) Holding History - GuruFocus
AstraZeneca says Truqap recommended by FDA advisory committee for prostate cancer - marketscreener.com
ASTRAZENECA : Jefferies reiterates its Buy rating - marketscreener.com
ASTRAZENECA : Receives a Buy rating from JP Morgan - marketscreener.com
FDA Panel Votes Against Benefits of AstraZeneca's Breast Cancer Drug - marketscreener.com
FDA panel rejects risk-benefit profile of AstraZeneca cancer drug - Reuters
FDA Panel Votes Against Benefit of Astra’s Breast Cancer Drug - Bloomberg.com
AstraZeneca Is a Buy as More Than 20 Phase III Readouts Loom - 24/7 Wall St.
FDA panel votes against backing AstraZeneca's breast cancer drug - marketscreener.com
Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsight - GlobeNewswire Inc.
AstraZeneca's Breast Cancer Drug Rejected by FDA on Safety Concerns, Bloomberg Reports - marketscreener.com
AstraZeneca Earnings: Off to a Great Start, With Major Readouts Expected Throughout the Year - Morningstar
Jennison Associates LLC Has $309.15 Million Holdings in Astrazeneca Plc $AZN - MarketBeat
Astrazeneca exercises option for Pinetree’s PTX-299 - BioWorld News
Citi raises AstraZeneca earnings forecast and maintains 'buy' rating ahead of second-half pipeline catalysts - Proactive financial news
AstraZeneca Outlook Strengthens on Pipeline Momentum - Kalkine Media
ASTRAZENECA : Deutsche Bank reaffirms its Sell rating - marketscreener.com
Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca - Quantisnow
AstraZeneca results: Q1 2026 - Quantisnow
AstraZeneca PLC (AZN) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
EBIT per share of AstraZeneca PLC – HAM:ZEG - TradingView
Astrazeneca injects £300m into UK sites - marketscreener.com
Astrazeneca Q1 Earnings Call Highlights - Yahoo Finance
AstraZeneca takes global rights to an EGFR cancer drug in $25M deal - Stock Titan
Astrazeneca (NYSE:AZN) Issues Quarterly Earnings Results - MarketBeat
AstraZeneca CEO says US MFN policy will have substantial impact on European drug launches, pricing - marketscreener.com
Correction to AstraZeneca Update - marketscreener.com
AstraZeneca Q1 2026 slides: pipeline delivers, revenue reporting raises questions - Investing.com
AstraZeneca plans to invest $405 million in Britain, PM Starmer says - marketscreener.com
AstraZeneca beats Q1 estimates, CEO says drug pipeline is 'delivering' - Yahoo Finance
AstraZeneca to make $405 million investment in Britain, PM Starmer says - marketscreener.com
AstraZeneca: Q1 Earnings Analysis: An Excellent Long-Term Buy And Hold (NYSE:AZN) - Seeking Alpha
What's Going On With AstraZeneca Stock Wednesday?AstraZeneca (NYSE:AZN) - Benzinga
AstraZeneca PLC 2026 Q1ResultsEarnings Call Presentation (NYSE:AZN) 2026-04-29 - Seeking Alpha
AstraZeneca revives Cambridge investment after UK agrees to pay more for drugs - Financial Times
0.85%
1.33%
자본화:
|
볼륨(24시간):